TAMPA, Fla., Oct. 10, 2016 -- The Eye Doctors, a full service eye care center in Tampa and New Port Richey, has announced that they are now providing an innovative new treatment for patients who suffer from dry eye caused by Meibomian Gland Dysfunction (MGD). MGD, a progressive disease that affects some 300 million people worldwide, stems from blockages in the oil-producing meibomian glands located in the eyelids. LipiFlow® unblocks the glands, allowing the glands to resume the secretion of oily lipids needed for a healthy tear film.
Developed as a result of 30 years of scientific research, LipiFlow® is an in-office procedure that uses directed heat and gentle pressure to liquefy and express the contents of meibomian glands. This cutting-edge treatment is FDA-cleared and scientifically proven. In a clinical study, 90 percent of patients achieved improvements in gland secretions after a single LipiFlow® treatment.
MGD can negatively impact long term vision and ocular health. If left untreated, MGD will worsen over time, leading to eye redness, dryness, irritation, burning, and eye fatigue. These symptoms can hinder daily activities such as reading, using the computer, wearing contact lenses, and being outdoors on windy days.
Patients who suffer from these symptoms should be screened for MGD as part of their routine comprehensive eye examination. Early identification of MGD can yield the best results for long term ocular health. LipiFlow® is an FDA-cleared treatment which safely and effectively treats the root cause of disease.
“Dry eye disease is one of the chief complaints that I hear from patients,” said Dr. Samuel Teske, optometrist at The Eye Doctors. “We are pleased to introduce LipiFlow® for our patients who are negatively impacted by MGD. Conventional therapies, such as warm compresses, over-the-counter wetting drops, ointments, and prescription drugs have failed to provide the relief that LipiFlow® offers. LipiFlow® is safe and the most effective treatment for MGD available today. Our patients have reported great improvement with their dry eye over the course of their treatment.”
About The Eye Doctors
The Eye Doctors provides an array of eye care services including comprehensive eye exams for all ages, dry eye treatment, eye disease management, and vision corrective services such as Ortho-K and CRT. Their team of eye care professionals have outstanding credentials to deliver the best care and outcomes for patients. The Eye Doctors utilizes the most advanced technology to deliver the best solutions safely and reliably to their patients.
Residents of the Tampa and New Port Richey communities who would like to schedule an appointment or who have questions regarding LipiFlow® treatments are invited to call The Eye Doctors at (813) 632-2020. For more information on the services and hours at this optometry clinic, visit their website at http://theeyedocs.com/.
The Eye Doctors, (813) 632-2020


Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 



